시장보고서
상품코드
1957450

mRNA 치료제 시장 보고서(2026년)

mRNA Therapeutics Global Market Report 2026

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

mRNA 치료제 시장 규모는 최근 꾸준히 확대하고 있습니다. 2025년 359억 달러에서 2026년에는 371억 8,000만 달러로, CAGR 3.6%로 성장할 것으로 예상됩니다. 지난 몇 년간의 성장은 감염병 분야에서 mRNA 백신의 획기적인 성공, 핵산 전달 기술의 발전, 유전자 발현 조절에 대한 이해의 심화, mRNA 기반 단백질 합성에 대한 초기 연구의 검증, mRNA 연구 플랫폼에 대한 강력한 공공 자금 지원 등에 기인하는 것으로 보입니다.

mRNA 치료제 시장 규모는 향후 몇 년간 꾸준한 성장이 전망됩니다. 2030년에는 423억 2,000만 달러에 달하고, CAGR은 3.3%가 될 전망입니다. 예측 기간의 성장 요인으로는 표적 치료제 및 맞춤의료에 대한 수요 증가, 종양학 및 희귀질환 분야에서의 mRNA 적용 확대, mRNA 파이프라인에 대한 바이오의약품 투자 증가, 임상시험 단계에 진입하는 mRNA 의약품의 증가, 생명공학 기업과 연구기관 간의 전략적 제휴 등을 꼽을 수 있습니다. 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 백신 이외의 mRNA 치료제의 확대, mRNA를 이용한 단백질 대체요법에 대한 관심 증가, 비백신 mRNA 의약품의 임상 파이프라인 증가, 지질 나노입자 전달 시스템에 대한 투자 확대, 엔드투엔드 mRNA 생산능력의 가속화 등을 들 수 있습니다.

향후 몇 년 동안 만성질환 및 감염성 질환의 발생률 증가가 mRNA 치료제 시장의 성장을 견인할 것으로 예상됩니다. 만성질환 및 전염성 질환은 결핵, HIV/에이즈, 간염 등의 질환을 포함하여 장기간 지속되고 개인 간 전염될 수 있는 질환을 말합니다. 이러한 질병의 증가는 주로 전 세계 이동의 증가와 의료 인프라 부족 등의 요인에 기인하며, 이는 전염률의 증가와 효과적인 질병 관리의 어려움으로 이어지고 있습니다. mRNA 치료제는 면역반응을 강화하는 단백질을 체내에서 빠르게 생성하게함으로써 더 나은 질병 관리를 돕고, 표적화된 백신 및 치료법의 신속한 개발을 지원합니다. 예를 들어, 미국 질병통제예방센터(CDC)에 따르면, 2024년 3월 기준 결핵 환자 수는 2022년 8,320명에서 2023년 9,615명으로 1,295명 증가했다고 합니다. 이처럼 만성질환 및 감염성 질환의 확산이 mRNA 치료제 시장의 성장을 견인하고 있습니다.

mRNA 치료제 시장에서 사업을 전개하는 주요 기업들은 암 환자의 면역 반응을 강화하고 생존율을 향상시키기 위해 맞춤형 신항원 백신과 같은 첨단 접근법 개발에 집중하고 있습니다. 맞춤형 신항원백신은 종양 특이적 유전자 변이를 활용하여 면역체계를 활성화시켜 암세포를 인식하고 제거하도록 설계된 환자별 맞춤형 암 치료법입니다. 예를 들어, 2023년 7월, 미국에 본사를 둔 연구중심 바이오제약 기업인 머크 앤 컴퍼니(Merck & Company)는 미국 바이오테크놀러지 기업인 모델나 테라퓨틱스(Modelna Therapeutics)와 공동으로 절제된 고위험군(Stage IIB-IV) 흑색종 환자를 대상으로 한 보조요법으로서 mRNA-4157(V940)과 키트루다(R)(펨브롤리주맙)의 병용요법을 절제된 고위험군(IIB-IV기) 흑색종 환자의 보조요법으로 평가하는 임상 3상 무작위배정 임상시험(V940-001)을 개시했습니다. 이번 임상은 임상 IIb상 KEYNOTE-942/mRNA-4157-P201 시험의 유망한 결과를 기반으로 하고 있습니다. 이번 임상에서 KEYTRUDA 단독요법 대비 병용요법이 재발 및 원격전이 위험 감소에 있어 유의미한 우월성을 입증했습니다. 임상 3상에서는 무재발생존기간을 1차 평가항목으로, 원격전이 무재발생존기간을 2차 평가항목으로 측정하여 이러한 결과를 검증하는 것을 목표로 하고 있습니다.

자주 묻는 질문

  • mRNA 치료제 시장 규모는 어떻게 변화하고 있나요?
  • mRNA 치료제 시장의 성장 요인은 무엇인가요?
  • mRNA 치료제가 만성질환 및 감염성 질환에 미치는 영향은 무엇인가요?
  • mRNA 치료제 시장에서 주요 기업들은 어떤 접근법을 개발하고 있나요?
  • 머크 앤 컴퍼니의 최근 임상시험에 대한 정보는 무엇인가요?

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별·국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

KSM

Messenger RNA (mRNA) therapeutics refer to a form of medical treatment that uses messenger RNA (mRNA) molecules to enable the production of therapeutic proteins inside the body. These therapies are applied to prevent, manage, or cure diseases by instructing cells to synthesize specific proteins required to achieve desired therapeutic outcomes.

The primary products of mRNA therapeutics include vaccines and drugs. Vaccines within the mRNA therapeutics segment are pharmaceutical formulations that utilize messenger RNA to direct cells to produce specific proteins, thereby stimulating an immune response against targeted diseases. These products are applicable across a wide range of areas such as infectious diseases, oncology, rare genetic disorders, respiratory diseases, and others, with end users including hospitals and clinics, research organizations, and others.

Tariffs have impacted the mRNA therapeutics market by increasing costs for importing specialized raw materials, lipid nanoparticles, enzymes, and bioprocessing equipment. These effects are most significant in regions reliant on global supply chains, particularly North America and Europe. Elevated production costs have influenced early-stage manufacturing and scale-up timelines. However, tariffs have also encouraged domestic manufacturing investments and regional supply chain localization, strengthening long-term market resilience.

The mrna therapeutics market research report is one of a series of new reports from The Business Research Company that provides mrna therapeutics market statistics, including mrna therapeutics industry global market size, regional shares, competitors with a mrna therapeutics market share, detailed mrna therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the mrna therapeutics industry. This mrna therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mrna therapeutics market size has grown steadily in recent years. It will grow from $35.9 billion in 2025 to $37.18 billion in 2026 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to breakthrough success of mrna vaccines in infectious diseases, advances in nucleic acid delivery technologies, increased understanding of gene expression control, early research validation of mrna-based protein synthesis, strong public funding for mrna research platforms.

The mrna therapeutics market size is expected to see steady growth in the next few years. It will grow to $42.32 billion in 2030 at a compound annual growth rate (CAGR) of 3.3%. The growth in the forecast period can be attributed to rising demand for targeted and personalized therapies, expansion of mrna applications in oncology and rare diseases, growing biopharmaceutical investment in mrna pipelines, increasing number of mrna drugs entering clinical trials, strategic partnerships between biotech firms and research organizations. Major trends in the forecast period include expansion of mrna therapeutics beyond vaccines, growing focus on protein replacement therapies using mrna, rising clinical pipeline for non-vaccine mrna drugs, increasing investment in lipid nanoparticle delivery systems, acceleration of end-to-end mrna manufacturing capabilities.

The rising incidence of chronic and communicable diseases is anticipated to drive the growth of the mRNA therapeutics market in the coming years. Chronic and communicable diseases are conditions that endure over long periods and can be transmitted between individuals, including diseases such as tuberculosis, HIV/AIDS, and hepatitis. The increase in these diseases is largely attributed to factors such as greater global mobility and deficiencies in healthcare infrastructure, which lead to higher transmission rates and challenges in effective disease control. mRNA therapeutics aid in better disease management by quickly enabling the body to generate proteins that strengthen immune responses, supporting the rapid development of targeted vaccines and therapies. For example, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Consequently, the growing prevalence of chronic and communicable diseases is fueling the expansion of the mRNA therapeutics market.

Major companies operating in the mRNA therapeutics market are concentrating on the development of advanced approaches, such as personalized neoantigen vaccines, to strengthen immune responses and enhance survival outcomes for cancer patients. Personalized neoantigen vaccines are individualized cancer treatments created for each patient by leveraging tumor-specific genetic mutations to activate the immune system to recognize and eliminate cancer cells. For example, in July 2023, Merck & Co., Inc., a US-based research-driven biopharmaceutical company, collaborated with Moderna Therapeutics, Inc., a US-based biotechnology firm, to launch a Phase 3 randomized clinical trial (V940-001) evaluating mRNA-4157 (V940) in combination with KEYTRUDA(R) (pembrolizumab) as an adjuvant therapy for patients with resected high-risk (Stage IIB-IV) melanoma. This trial builds on encouraging outcomes from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, which demonstrated a significant advantage of the combination therapy over KEYTRUDA alone in lowering the risk of recurrence and distant metastasis. The Phase 3 study is designed to validate these results by measuring relapse-free survival and distant metastasis-free survival as the primary and secondary endpoints, respectively.

In June 2025, BioNTech SE, a biotechnology company based in Germany, acquired CureVac N.V. for an undisclosed sum. Through this acquisition, BioNTech SE seeks to enhance its capabilities in the research, development, manufacturing, and commercialization of mRNA-based cancer immunotherapy candidates, representing a significant milestone in its oncology strategy to accelerate innovative cancer therapies and set new standards of care in the years ahead. CureVac N.V. is a Germany-based company specializing in the development of mRNA-based therapies.

Major companies operating in the mrna therapeutics market are Pfizer Inc., Novartis AG, Sanofi AG, AstraZeneca plc, GlaxoSmithKline plc, Hoffmann-La Roche AG, Moderna Therapeutics Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Catalent Inc, Alnylam Pharmaceuticals Inc, Sarepta Therapeutics Inc, Arcturus Therapeutics Holdings Inc, CureVac N.V, Ethris GMBH, eTheRNA immunotherapies NV, In-Cell-Art S.A.S., Nutcracker Therapeutics Inc, SCM LifeScience Co Ltd, Suzhou Abogen Biosciences Co Ltd, Tiba Biotech LLC, CSPC Pharmaceutical Group, CRISPR Therapeutics AG

North America was the largest region in the mRNA therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mrna therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mRNA therapeutics market consists of revenues earned by entities by providing services such as vaccine development, protein replacement therapies, gene editing, monoclonal antibody production, and cancer treatment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

mRNA Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses mrna therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mrna therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mrna therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Product: Vaccines; Drugs
  • 2) By Application: Infectious Diseases; Oncology; Rare Genetic Diseases; Respiratory Diseases; Other Applications
  • 3) By End Use: Hospitals And Clinics; Research Organizations; Other End Uses
  • Subsegments:
  • 1) By Vaccines: Infectious Disease Vaccines; Cancer Vaccines; Other Therapeutic Vaccines
  • 2) By Drugs: Oncology Drugs; Cardiovascular Drugs; Autoimmune Disease Drugs; Other mRNA-Based Drugs
  • Companies Mentioned: Pfizer Inc.; Novartis AG; Sanofi AG; AstraZeneca plc; GlaxoSmithKline plc; Hoffmann-La Roche AG; Moderna Therapeutics Inc; BioNTech SE; Vertex Pharmaceuticals Incorporated; Catalent Inc; Alnylam Pharmaceuticals Inc; Sarepta Therapeutics Inc; Arcturus Therapeutics Holdings Inc; CureVac N.V; Ethris GMBH; eTheRNA immunotherapies NV; In-Cell-Art S.A.S.; Nutcracker Therapeutics Inc; SCM LifeScience Co Ltd; Suzhou Abogen Biosciences Co Ltd; Tiba Biotech LLC; CSPC Pharmaceutical Group; CRISPR Therapeutics AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. mRNA Therapeutics Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global mRNA Therapeutics Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. mRNA Therapeutics Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global mRNA Therapeutics Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Expansion Of Mrna Therapeutics Beyond Vaccines
    • 4.2.2 Growing Focus On Protein Replacement Therapies Using Mrna
    • 4.2.3 Rising Clinical Pipeline For Non-Vaccine Mrna Drugs
    • 4.2.4 Increasing Investment In Lipid Nanoparticle Delivery Systems
    • 4.2.5 Acceleration Of End-To-End Mrna Manufacturing Capabilities

5. mRNA Therapeutics Market Analysis Of End Use Industries

  • 5.1 Hospitals And Clinics
  • 5.2 Research Organizations
  • 5.3 Biotechnology Companies
  • 5.4 Pharmaceutical Companies
  • 5.5 Academic And Translational Research Institutes

6. mRNA Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global mRNA Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global mRNA Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global mRNA Therapeutics Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global mRNA Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global mRNA Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global mRNA Therapeutics Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. mRNA Therapeutics Market Segmentation

  • 9.1. Global mRNA Therapeutics Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Vaccines, Drugs
  • 9.2. Global mRNA Therapeutics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Infectious Diseases, Oncology, Rare Genetic Diseases, Respiratory Diseases, Other Applications
  • 9.3. Global mRNA Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals And Clinics, Research Organizations, Other End Uses
  • 9.4. Global mRNA Therapeutics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Infectious Disease Vaccines, Cancer Vaccines, Other Therapeutic Vaccines
  • 9.5. Global mRNA Therapeutics Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oncology Drugs, Cardiovascular Drugs, Autoimmune Disease Drugs, Other mRNA-Based Drugs

10. mRNA Therapeutics Market Regional And Country Analysis

  • 10.1. Global mRNA Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global mRNA Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific mRNA Therapeutics Market

  • 11.1. Asia-Pacific mRNA Therapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China mRNA Therapeutics Market

  • 12.1. China mRNA Therapeutics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India mRNA Therapeutics Market

  • 13.1. India mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan mRNA Therapeutics Market

  • 14.1. Japan mRNA Therapeutics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia mRNA Therapeutics Market

  • 15.1. Australia mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia mRNA Therapeutics Market

  • 16.1. Indonesia mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea mRNA Therapeutics Market

  • 17.1. South Korea mRNA Therapeutics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan mRNA Therapeutics Market

  • 18.1. Taiwan mRNA Therapeutics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia mRNA Therapeutics Market

  • 19.1. South East Asia mRNA Therapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe mRNA Therapeutics Market

  • 20.1. Western Europe mRNA Therapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK mRNA Therapeutics Market

  • 21.1. UK mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany mRNA Therapeutics Market

  • 22.1. Germany mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France mRNA Therapeutics Market

  • 23.1. France mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy mRNA Therapeutics Market

  • 24.1. Italy mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain mRNA Therapeutics Market

  • 25.1. Spain mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe mRNA Therapeutics Market

  • 26.1. Eastern Europe mRNA Therapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia mRNA Therapeutics Market

  • 27.1. Russia mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America mRNA Therapeutics Market

  • 28.1. North America mRNA Therapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA mRNA Therapeutics Market

  • 29.1. USA mRNA Therapeutics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada mRNA Therapeutics Market

  • 30.1. Canada mRNA Therapeutics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America mRNA Therapeutics Market

  • 31.1. South America mRNA Therapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil mRNA Therapeutics Market

  • 32.1. Brazil mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East mRNA Therapeutics Market

  • 33.1. Middle East mRNA Therapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa mRNA Therapeutics Market

  • 34.1. Africa mRNA Therapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa mRNA Therapeutics Market, Segmentation By Product, Segmentation By Application, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. mRNA Therapeutics Market Regulatory and Investment Landscape

36. mRNA Therapeutics Market Competitive Landscape And Company Profiles

  • 36.1. mRNA Therapeutics Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. mRNA Therapeutics Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. mRNA Therapeutics Market Company Profiles
    • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Sanofi AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

37. mRNA Therapeutics Market Other Major And Innovative Companies

  • Hoffmann-La Roche AG, Moderna Therapeutics Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Catalent Inc, Alnylam Pharmaceuticals Inc, Sarepta Therapeutics Inc, Arcturus Therapeutics Holdings Inc, CureVac N.V, Ethris GMBH, eTheRNA immunotherapies NV, In-Cell-Art S.A.S., Nutcracker Therapeutics Inc, SCM LifeScience Co Ltd, Suzhou Abogen Biosciences Co Ltd

38. Global mRNA Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The mRNA Therapeutics Market

40. mRNA Therapeutics Market High Potential Countries, Segments and Strategies

  • 40.1 mRNA Therapeutics Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 mRNA Therapeutics Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 mRNA Therapeutics Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제